A four-story laboratory facility will also be included to enable the company to increase production capacity for approved medicines.
The company employs more than 500 people in Ireland and has created investment plans spanning 13 years in the region. The facility in Cork is BioMarin's only one outside of the US, producing medicines from bulk drug substance to final packaging.
“This investment in our Cork facility reflects our ongoing commitment to enhancing our industry-leading global manufacturing capabilities and supporting the growth of our innovative medicines for our people living with rare conditions around the world,” said Evelyn Marchany Garcia, Senior Vice President, Chief Quality Officer, BioMarin Pharmaceutical. “The Shanbally facility plays a crucial role in our global network, and this expansion emphasises our confidence in Ireland’s skilled workforce and the strategic importance of this site to BioMarin’s long-term success."
Michael Lohan, CEO, IDA Ireland said, “As a global leader in the biopharmaceutical sector, BioMarin’s ongoing investment in Ireland is a welcome endorsement of the country’s position globally as a location of choice for biopharmaceuticals and a trailblazer in advancing healthcare solutions. By opening this new quality control and process development laboratory, BioMarin will create new opportunities for collaboration, talent development and growth, ensuring that the life sciences sector in Ireland continues to make an impact on patients’ lives worldwide.”
